PTO/SB/08a (05-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10520372	
	Filing Date		2006-01-09	
	First Named Inventor Asim		Kumar Ray	
	Art Unit			
	Examiner Name			
	Attorney Docket Number	er	133087.09801	

U.S.PATENTS										Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date		Name of Pate of cited Docu	entee or Applicant ment	Pages,Columns,Lines where Relevant Passages or Releva Figures Appear				
	1											
If you wish to add additional U.S. Patent citation information please click the Add button.												
U.S.PATENT APPLICATION PUBLICATIONS Remove												
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1											
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add											
FOREIGN PATENT DOCUMENTS Remove												
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patentee Applicant of cited Document	or V F	vhere Rele	or Relevant	T5	
	1	0247456	WO			2002-06-20	SmithKline Beechal Corporation	m				
	2	04087680	WO			2004-10-14	Taisho Pharm.					
	3	2004315511	JP			2004-11-11	Taisho Pharm.					

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10520372			
Filing Date		2006-01-09			
First Named Inventor	Asim	Asim Kumar Ray			
Art Unit					
Examiner Name					
Attorney Docket Number		133087.09801			

	4	9720823	WO		1997-06-12	Novartis AG				
	5	0404726	wo		2004-01-15	AstraZeneca AB				
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials*	Cite No	I (DOOK madazine journal serial symposium catalog etc) date pades(s) volume-issue number(s)								
	1	Jarvest et al., "Conformational restriction of methionyl tRNA synthetase inhibitors leading to analogues with potent inhibition and excellent gram-positive antibacterial activity," Bioorg Med Chem Lett (2003) 13(7):1265-1268.								
	2	Giardina et al., "Structure-activity relationships in prazosin-related compounds. 2. Role of the piperazine ring on alphablocking activity," J Med Chem (1993) 36:690-698.								
	3	Notice of copending applications.								
If you wis	h to ac	dd additional non-pater	nt literature docui	ment cit	ation informati	on please click the Add b	outton Add			
EXAMINER SIGNATURE										
Examiner	Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										
<sup>1</sup> See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.										